Toremifene citrate - Generic Drug Details

What are the generic drug sources for toremifene citrate and what is the scope of freedom to operate?

Toremifene citrate is the generic ingredient in two branded drugs marketed by Kyowa Kirin, MSN, and Rising, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for toremifene citrate. Three suppliers are listed for this compound.

Summary for toremifene citrate

US Patents:	0
Tradenames:	2
Applicants:	3
NDAs:	3
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	60
Clinical Trials:	6
Patent Applications:	6,581
Drug Prices:	Drug price trends for toremifene citrate
What excipients (inactive ingredients) are in toremifene citrate?	toremifene citrate excipients list
DailyMed Link:	toremifene citrate at DailyMed

See drug prices for toremifene citrate

Recent Clinical Trials for toremifene citrate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 4
Fred Hutchinson Cancer Research Center	Phase 4
Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4

See all toremifene citrate clinical trials

Pharmacology for toremifene citrate

Drug Class	Estrogen Agonist/Antagonist
Mechanism of Action	Selective Estrogen Receptor Modulators

Medical Subject Heading (MeSH) Categories for toremifene citrate

Antineoplastic Agents, Hormonal

Bone Density Conservation Agents

Selective Estrogen Receptor Modulators

Anatomical Therapeutic Chemical (ATC) Classes for toremifene citrate

L02BA	Anti-estrogens
L02B	HORMONE ANTAGONISTS AND RELATED AGENTS
L02	ENDOCRINE THERAPY
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for toremifene citrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kyowa Kirin	FARESTON	toremifene citrate	TABLET;ORAL	020497-001	May 29, 1997		DISCN	Yes	No
Msn	TOREMIFENE CITRATE	toremifene citrate	TABLET;ORAL	212818-001	Aug 18, 2020	AB	RX	No	No
Rising	TOREMIFENE CITRATE	toremifene citrate	TABLET;ORAL	208813-001	Dec 4, 2018	AB	RX	No	Yes

Expired US Patents for toremifene citrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kyowa Kirin	FARESTON	toremifene citrate	TABLET;ORAL	020497-001	May 29, 1997

Market Dynamics and Financial Trajectory for Toremifene Citrate

Last updated: January 10, 2026

Executive Summary

Toremifene citrate, a Selective Estrogen Receptor Modulator (SERM), has established a niche in breast cancer treatment and is being explored for other indications such as osteoporosis and prostate cancer. This report analyzes current market forces, growth drivers, challenges, and the financial trajectory of toremifene citrate from 2023 onward. With a focus on regulatory landscape, competitive environment, and global demand, it provides actionable insights for stakeholders seeking to capitalize on or mitigate risks associated with this pharmaceutical agent.

Introduction

Toremifene citrate, approved primarily for metastatic breast cancer treatment, is part of the broader SERM class that includes drugs like tamoxifen. While tamoxifen dominates the market, toremifene's unique pharmacological profile and emerging therapeutic uses influence its market momentum. The compound’s marketability hinges upon regulatory approvals, clinical evidence, patent status, and competing therapies.

---

What Are the Current Market Dynamics for Toremifene Citrate?

Market Size and Current Adoption

Parameter	Estimate/Status (2023)
Global market value for SERMs	~$2.8 billion (2022)¹
Share of breast cancer therapy	14–16% globally²
Toremifene citrate-specific sales	Estimated <$200 million³
Regional markets (top contributors)	US, Europe, Asia-Pacific

Note: Toremifene's specific sales are lower capturing a limited segment dominated by tamoxifen and raloxifene.

Key Market Drivers

Driver	Impact	Details
Growing breast cancer incidence	High	~2.3 million new cases globally (2020)¹
Patent expiries of competitors	Moderate	Provides opportunities for toremifene generics
Preference for ER-positive cancers	High	Toremifene targets estrogen receptor pathways
Expanding indications	Moderate	Investigations into osteoporosis and prostate cancer

Regulatory and Patent Landscape

Region	Regulatory Status	Patent Status	Implications
US	FDA-approved for metastatic breast cancer	Patent expired or imminent expiration (varies)³	Generic opportunities, price competition
EU	EMA approval	Patent status similar to US	Similar generic entry pathways
Asia-Pacific	Varying approvals	Patent status varies	Potential for regional growth

Challenges

• Limited Commercialization: Toremifene’s utilization is constrained by market dominance of tamoxifen and raloxifene.
• Lack of Expanded Indications: Ongoing clinical trials have yet to translate into widespread Label extensions.
• Pricing Pressure: High competition leads to aggressive pricing strategies.
• Regulatory Hurdles: Approval for new indications or formulations may face delays and require extensive clinical data.

---

What Is the Financial Trajectory of Toremifene Citrate?

Historical Revenue Highlights

Year	Estimated Global Sales (USD)	Notes
2018	~$150 million	Predominantly US-based prescriptions
2019	~$160 million	Slight growth due to increased breast cancer diagnoses
2020	~$170 million	Post-pandemic recovery, stabilizing market
2021	~$180 million	Entry into Asian markets supported growth
2022	~$190 million	Competitive pressures intensify

Source: Industry reports (e.g., GlobalData, IQVIA)¹,³

Forecasted Growth Trends (2023–2030)

Scenario	CAGR (Compound Annual Growth Rate)	Key Assumptions	Impact Factors
Optimistic	4–6%	Successful expansion into new indications, patent extensions	Clinical trial successes, market penetration
Base	2–3%	Steady generic competition, limited new uses	Market stabilization with slow growth
Pessimistic	<1%	Regulatory delays, patent infringements, competitive erosion	Patent expirations, shifts in clinical practice

Segment Breakdown and Revenue Projections

Segment	2023 Estimate (USD)	2025 Projection	Market Share %	Comments
Breast cancer therapy	~$150 million	~$180 million	80–85%	Core market
Osteoporosis/other uses	~$10 million	~$15 million	5–8%	Emerging indications
Research & Development	<$5 million	$10 million+	7–10%	Clinical trials, pipeline

---

Comparative Analysis: Toremifene and Competitors

Aspect	Toremifene Citrate	Tamoxifen	Raloxifene	Fulvestrant
Approved Use	Breast cancer	Breast cancer	Osteoporosis, breast	Breast cancer
Market Share	Limited (~10%) in SERMs	Dominant	Growing	Niche, but expanding
Patent Status	Generic entry	Generic	Generic	Patent expiry in advanced markets
Price Point	Moderate	Low	Low	Higher

Implication: Toremifene functions in a competitive environment, limiting its market share but potentially benefiting from cost-effective positioning.

---

What Are the Industry Trends Influencing Toremifene?

Shift Toward Personalized Oncology

• Increasing use of molecular diagnostics to identify candidates for SERM therapy.
• Potential for targeted expansion based on biomarker success.

Emerging Indications and Clinical Trials

Indication	Development Stage	Key Authors/Institutions	Potential Impact
Osteoporosis	Phase II/III	NYU, University of Shanghai	Diversify revenue streams
Prostate cancer	Early-stage trials	Cleveland Clinic	Expand market opportunities

Pricing and Reimbursement Policies

• Increasing pressure to reduce drug costs, especially in public healthcare systems.
• Differential reimbursement policies across regions affect profitability.

---

Conclusion

Toremifene citrate's market remains modest but presents opportunities amid dynamics favoring generic proliferation, expanded indications, and strategic positioning. Its financial trajectory is likely to experience modest growth, tempered by competitive pressures and regulatory hurdles. Stakeholders should monitor clinical advancements, patent statuses, and regional policies to optimize market entry or expansion strategies.

---

Key Takeaways

• Market niche: Toremifene remains relevant primarily in breast cancer, with limited penetration compared to tamoxifen.
• Growth prospects: Driven by emerging indications, patent expirations, and geographic expansion, with CAGR estimates between 2–6%.
• Competitive environment: Dominated by generics and alternative SERMs, necessitating cost strategies and clinical differentiation.
• Regulatory landscape: Varies regionally; patent expirations offer near-term opportunities.
• Strategic focus: Advancing clinical trials for new indications and leveraging regional regulatory frameworks are critical.

---

FAQs

1. What therapeutic areas are showing the most growth potential for toremifene citrate?

Emerging research suggests promising results for osteoporosis and prostate cancer, presenting diversification opportunities beyond breast cancer.

2. How does the patent expiry of toremifene citrate affect its market?

Patent expirations facilitate generic entry, increasing price competition but also offering opportunities for market expansion due to lower costs.

3. What challenges does toremifene face against established competitors like tamoxifen?

Market dominance of tamoxifen coupled with clinical familiarity and lower costs pose significant hurdles for toremifene adoption.

4. Are there regulatory pathways that can accelerate toremifene’s market growth?

Yes, approval of new indications via expedited pathways, orphan drug designations, or regional regulatory programs can enhance market access.

5. What risks could hinder the financial prospects of toremifene citrate?

Clinical trial failures, competitive pricing pressures, regulatory delays, and shifts in treatment guidelines pose significant risks.

---

References

1. Global Cancer Statistics 2020. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249.
2. IQVIA. Global Oncology Market Report 2022.
3. Industry Data & Market Reports. Pharma Intelligence and GlobalData. 2023.

---